Articles: nausea.
-
Br J Clin Pharmacol · Mar 1985
Randomized Controlled Trial Clinical TrialThe evaluation of domperidone and metoclopramide as antiemetics in day care abortion patients.
A randomised double-blind investigation was undertaken to assess the value of domperidone and metoclopramide as prophylactic anti-emetics in unpremedicated patients undergoing general anaesthesia for therapeutic abortion on a day care basis. Sixty patients were divided into three groups, and received, at induction, one of three drugs intravenously. The incidences of postoperative nausea and vomiting were 35% in the group receiving normal saline as placebo, 30% in the group receiving 10 mg domperidone and 25% in the group receiving 10 mg metoclopramide; these were not statistically significantly different. Furthermore, there was no statistically significant difference in the incidence of postoperative nausea and vomiting as influenced by age, weight, length of gestation, anaesthetic time and a history of nausea and vomiting during the pregnancy.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Nausea and vomiting in day-case dental anaesthesia. The use of low-dose droperidol.
The anti-emetic effects of low-dose droperidol (1.25 mg), ultra-low-dose droperidol (0.25 mg) and a placebo were compared in patients admitted for day-case dental anaesthesia. Ultra-low-dose droperidol produced a significant decrease in the subjective feeling of nausea without delaying recovery or discharge from the hospital (p less than 0.05). Low-dose droperidol did not significantly reduce nausea (p greater than 0.05) and prolonged the recovery time (p less than 0.05).
-
Ann R Coll Surg Engl · Sep 1984
Randomized Controlled Trial Comparative Study Clinical TrialEvaluation of anti-emetics in association with intrathecal diamorphine.
Intrathecal diamorphine is associated with a high incidence of emetic symptoms. Six anti-emetic drugs representing various chemical groups were given in random order to patients undergoing total hip replacement and who had received intrathecal diamorphine 0.5-1.0 mg. The phenothiazines, perphenazine and prochlorperazine, were more effective than the others. It is suggested that this might be a useful model for the evaluation of new anti-emetics.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy.
We conducted a randomized, double-blind, crossover study comparing the antiemetic efficacy of dexamethasone and prochlorperazine in 42 patients with cancer who were receiving outpatient chemotherapy, mainly without cisplatin. Patients experienced significantly less nausea and vomiting with dexamethasone than with prochlorperazine (P less than 0.02 and less than 0.03, respectively). Twenty-five patients experienced no nausea with dexamethasone, as compared with 14 patients taking prochlorperazine (P less than 0.001). ⋯ Somnolence was the most frequent side effect, occurring in 60 per cent of patients receiving prochlorperazine and in 12 per cent of those receiving dexamethasone (P less than 0.001). Patients also experienced less suppression of appetite while receiving dexamethasone (P less than 0.02). We conclude that dexamethasone is an effective and safe antiemetic in patients receiving cancer chemotherapy without cisplatin.
-
Randomized Controlled Trial Clinical Trial
Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy.
The nausea and vomiting experienced by one in four cancer patients in anticipation of chemotherapy is probably a learned response to treatment. To determine whether behavioral approaches for altering learned responses might be useful treatments for these symptoms, we compared the effects of "systematic desensitization" (a behavioral treatment in which relaxation is learned as a response to situations in which patients have had anticipatory nausea and vomiting) with those of counseling and of no treatment. ⋯ Desensitized patients also reported significantly less severe anticipatory nausea (P less than 0.01) and vomiting (P less than 0.05) and a shorter duration of anticipatory nausea (P less than 0.01). We conclude that systematic desensitization appears to have an antiemetic effect in cancer patients who receive chemotherapy, and may be useful in the management of these problems.